Molecules / Olmesartan Medoxomil / India

Olmesartan Medoxomil API manufacturers in India

CAS 144689-63-4 Updated 9 July 2026
23
India-based manufacturers with an active filing of 25 worldwide
$303.99
median export price per kg, all origins $142.00 to $595.65 · 33 exporters · 2025
Showing 13 of 23 India-based manufacturers This list is ranked on evidence. Placement cannot be purchased.

Ranked India-based API manufacturers

01

Cadila Pharmaceuticals

India
Makes the API
Credentials confirmed against the regulator files on 25 July 2026

Holds one valid CEP for olmesartan medoxomil, filing since 2024. Its 2025 FDA inspection closed as NAI, and its GMP is recognised in 15 markets.

US DMF
None on file
CEP
1 valid
Last FDA inspection
2025 · NAI
GMP recognised in
15 markets
How this listing is sourced EDQM certificate database
View profile
02

Hetero

India
Makes the APIFinished dose
Credentials confirmed against the regulator files on 25 July 2026

Holds 2 valid CEPs for olmesartan medoxomil, filing since 2024. Its 2025 FDA inspection closed as NAI, and its GMP is recognised in 23 markets.

US DMF
None on file
CEP
2 valid
Last FDA inspection
2025 · NAI
GMP recognised in
23 markets
03

Macleods Pharmaceuticals

India
Makes the APIFinished dose
Credentials confirmed against the regulator files on 25 July 2026

Holds 2 valid CEPs for olmesartan medoxomil, filing since 2025. Its 2024 FDA inspection closed as VAI, and its GMP is recognised in 29 markets.

US DMF
None on file
CEP
2 valid
Last FDA inspection
2024 · VAI
GMP recognised in
29 markets
How this listing is sourced EDQM certificate database
View profile
04

Torrent Pharmaceuticals

India
Makes the APIFinished dose
Credentials confirmed against the regulator files on 25 July 2026

Holds one valid CEP for olmesartan medoxomil, filing since 2026. Its 2026 FDA inspection closed as NAI, and its GMP is recognised in 20 markets.

US DMF
None on file
CEP
1 valid
Last FDA inspection
2026 · NAI
GMP recognised in
20 markets
How this listing is sourced EDQM certificate database
View profile
05

Alembic Pharmaceuticals

India
Makes the APIFinished dose
Credentials confirmed against the regulator files on 25 July 2026

Holds 2 valid CEPs for olmesartan medoxomil, filing since 2026. Its 2025 FDA inspection closed as VAI, and its GMP is recognised in 18 markets.

US DMF
None on file
CEP
2 valid
Last FDA inspection
2025 · VAI
GMP recognised in
18 markets
How this listing is sourced EDQM certificate database
View profile
06

MSN Laboratories

India
Makes the APIFinished dose
Credentials confirmed against the regulator files on 25 July 2026

Holds one valid CEP for olmesartan medoxomil, filing since 2025. Its 2025 FDA inspection closed as VAI, and its GMP is recognised in 26 markets.

US DMF
None on file
CEP
1 valid
Last FDA inspection
2025 · VAI
GMP recognised in
26 markets
How this listing is sourced EDQM certificate database
View profile
07

Micro Labs

India
Makes the APIFinished dose
Credentials confirmed against the regulator files on 25 July 2026

Holds 2 valid CEPs for olmesartan medoxomil, filing since 2023. Its 2025 FDA inspection closed as VAI, and its GMP is recognised in 20 markets.

US DMF
None on file
CEP
2 valid
Last FDA inspection
2025 · VAI
GMP recognised in
20 markets
How this listing is sourced EDQM certificate database
View profile
08

Zydus Lifesciences

India
Makes the APIFinished dose
Credentials confirmed against the regulator files on 25 July 2026

Holds one valid CEP for olmesartan medoxomil, filing since 2023. Its 2025 FDA inspection closed as VAI, and its GMP is recognised in 25 markets.

US DMF
None on file
CEP
1 valid
Last FDA inspection
2025 · VAI
GMP recognised in
25 markets
How this listing is sourced EDQM certificate database
View profile
09

Alivus Life Sciences

India
Makes the API
Credentials confirmed against the regulator files on 25 July 2026

Holds 2 valid CEPs for olmesartan medoxomil, filing since 2025. Its 2025 FDA inspection closed as NAI, and its GMP is recognised in 1 market.

US DMF
None on file
CEP
2 valid
Last FDA inspection
2025 · NAI
GMP recognised in
1 markets
10

Morepen Laboratories

India
Makes the API
Credentials confirmed against the regulator files on 25 July 2026

Holds one valid CEP for olmesartan medoxomil, filing since 2024. Its 2023 FDA inspection closed as NAI, and its GMP is recognised in 2 markets.

US DMF
None on file
CEP
1 valid
Last FDA inspection
2023 · NAI
GMP recognised in
2 markets
How this listing is sourced EDQM certificate database
View profile
11

Viyash Life Sciences

India
Makes the API
Credentials confirmed against the regulator files on 25 July 2026

Holds one valid CEP for olmesartan medoxomil, filing since 2025. Its 2025 FDA inspection closed as VAI.

US DMF
None on file
CEP
1 valid
Last FDA inspection
2025 · VAI
GMP recognised in
Not established
How this listing is sourced EDQM certificate database
View profile

10 more manufacturers in India hold filings for olmesartan medoxomil

The names are listed below. The filings, inspection history and GMP certificates behind each one are available with a free account.

Open the full list with a free account

How this list is built

This page filters the worldwide Olmesartan Medoxomil manufacturer list to companies based in India. The order is set by active filings weighted by regulator, inspection outcomes and their recency, breadth of GMP recognition, and evidence of real exports, less any open risk flags. Read the full method.

Map olmesartan medoxomil for your markets

Tell us which markets you need to file in. These suppliers come back tiered for those markets, with the price corridor and an RFI sheet.

Start for free
No sales call.

All Olmesartan Medoxomil manufacturers